• This record comes from PubMed

Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness

. 2025 ; 2025 (1) : niaf007. [epub] 20250419

Status PubMed-not-MEDLINE Language English Country Great Britain, England Media electronic-ecollection

Document type Journal Article

5-MeO-DMT is a short-acting psychedelic that is anecdotally reported to induce a radical disruption of the self and a paradoxical quality of aroused, waking awareness that is nevertheless devoid of any specific perceptual contents. Here, we conducted an exploratory observational study of the phenomenological and neuronal effects of this compound. We collected micro-phenomenological interviews, psychometric questionnaires, and electroencephalography (EEG) in naturalistic ceremonial settings where 5-MeO-DMT was ingested. Results revealed that the 5-MeO-DMT experience followed a dynamic progression that-only in the most extreme cases-manifested as a complete absence of self-experience and other phenomenal content with preserved awareness. Furthermore, visual imagery, bodily self-disruption, narrative self-disruption, and reduced phenomenal distinctions occurred in a variable fashion. EEG analyses revealed the 5-MeO-DMT experience was characterised by (global) alpha and (posterior) beta power reductions, implying a mode of brain functioning where top-down models are inhibited. Our preliminary phenomenological findings confirm the potential utility of 5-MeO-DMT as a pharmacological model for deconstructed consciousness while noting the limitations of employing retrospective questionnaires for this purpose. Considering the exploratory nature of this study and its limitations inherent to its naturalistic nature, further research employing real-time experience sampling and phenomenologically trained participants in controlled environments could expand our findings to meaningfully inform the potential of this tool for the scientific study of consciousness.

See more in PubMed

Acosta-Urquidi  J. EEG studies of the acute effects of the visionary tryptamine DMT. In: Columbus  AM (ed.),

Blackburne  G, McAlpine  RG, Fabus  M  et al.  Complex slow waves radically reorganise human brain dynamics under 5-MeO-DMT. 2024. doi: 10.1101/2024.10.04.616717 DOI

Carhart-Harris  RL, Friston  KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. PubMed DOI PMC

Carhart-Harris  RL, Leech  R, Hellyer  PJ  et al.  The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. PubMed DOI PMC

Clarke  V, Braun  V. Thematic analysis. DOI

Ermakova  AO, Dunbar  F, Rucker  J  et al. A narrative synthesis of research with 5-MeO-DMT. PubMed DOI PMC

Erritzoe  D, Timmermann  C, Godfrey  K  et al. Exploring mechanisms of psychedelic action using neuroimaging. DOI

Mediano  PA, Rosas  FE, Luppi  AI  et al.  Spectrally and temporally resolved estimation of neural signal diversity. DOI

Metzinger  T. Minimal phenomenal experience meditation, tonic alertness, and the phenomenology of.

Metzner  R. The Toad and the Jaguar: A Field Report of Underground Research on a Visionary Medicine Bufo alvarius and 5-methoxy-dimethyltryptamine. Berkeley, CA: Regent Press, 2013.

Nichols  DE. Psychedelics. PubMed PMC

Ona  G, Sampedro  F, Romero  S  et al. The kappa opioid receptor and the sleep of reason: cortico-subcortical imbalance following salvinorin-A. PubMed DOI PMC

Oostenveld  R, Fries  P, Maris  E  et al.  Fieldtrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. PubMed DOI PMC

Pallavicini  C, Cavanna  F, Zamberlan  F  et al.  Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings. PubMed DOI

Petitmengin  C. Describing one’s subjective experience in the second person: an interview method for the science of consciousness. DOI

Petitmengin  C, Remillieux  A, Cahour  B  et al.  A gap in Nisbett and Wilson’s findings? A first-person access to our cognitive processes. PubMed DOI

Petitmengin  C, Remillieux  A, Valenzuela-Moguillansky  C. Discovering the structures of lived experience: towards a micro-phenomenological analysis method. DOI

Roseman  L, Nutt  DJ, Carhart-Harris  RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. PubMed DOI PMC

Studerus  E, Gamma  A, Vollenweider  FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PubMed DOI PMC

Timmermann  C. The Effects of DMT and Associated Psychedelics on the Human Mind and Brain. London: Imperial College London, 2020.

Timmermann  C, Bauer  PR, Gosseries  O  et al. A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. PubMed DOI

Timmermann  C, Roseman  L, Haridas  S  et al. Human brain effects of DMT assessed via EEG-fMRI. PubMed DOI PMC

Timmermann  C, Roseman  L, Schartner  M  et al. Neural correlates of the DMT experience assessed with multivariate EEG. PubMed DOI PMC

Timmermann  C, Watts  R, and Dupuis  D. Towards psychedelic apprenticeship: developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. PubMed DOI PMC

Trautwein  FM, Schweitzer  Y, Dor-Ziderman  Y  et al.  Suspending the embodied self in meditation attenuates beta oscillations in the posterior medial cortex. PubMed DOI PMC

Uthaug  MV, Lancelotta  R, Szabo  A  et al.  Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. PubMed DOI PMC

Yeshurun  Y, Nguyen  M, Hasson  U. The default mode network: where the idiosyncratic self meets the shared social world. PubMed DOI PMC

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...